Pay in 4 interest-free payments of $5.81 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Summary: Retatrutide FDA Status Retatrutide is not FDA-approved and won't be for at least another year It's in Phase 3 trials (TRIUMPH program) with results expected in late 2026 FDA approval is projected for 20272028 Phase 2 data showed 24.2% weight loss , better than any approved GLP-1 medication Current access: clinical trials (free), compounded retatrutide ($200$500/mo), or research peptides ($150$500/mo) When approved, retatrutide will be the first triple-agonist obesity medication on the market References Jastreboff AM, Aronne LJ, Ahmad NN, et al
Retatrutide is an investigational compound that is not approved by the FDA or EMA and is not a medicine
The latter is another good choice for the formula its in, as a 2022 study concluded that it may help prevent metabolic disorders associated with a high-fat diet (in mice).31 Again, though, were talking about a large dose, with the study calculating a human-equivalent dose to be 1020g per day
Early clinical research suggests retatrutide may support chronic weight management and metabolic health, but it is not yet FDA-approved or legally available by prescription
Rosenthal SB
Country of Origin: USA Manufacturer/Importer/Packed By : Bio.Me Country of Origin: USA Manufacturer/Importer/Packed By : Bio.Me
US$ 22.80
US$ 26.59
US$ 22.56
US$ 21.29
US$ 23.92
US$ 27.20
